fosinopril

Fosinopril, a phosphinic acid-containing angiotensin-converting enzyme inhibitor, is effective in hypertension treatment. Fosinopril is a prodrug that is converted to its active metabolite fosinoprilat.

Fosinopril sodium is a phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.

Fosinopril-d7 is intended for use as an internal standard for the quantification of fosinopril by GC- or LC-MS. Fosinopril is a prodrug form of the angiotensin-converting enzyme inhibitor fosinoprilat. Oral administration of fosinopril inhibits angiotensin I-induced pressor responses in normotensive rats, dogs, and monkeys when administered at doses of 15, 15, and 10 µmol/kg, respectively. Fosinopril reduces fractional shortening and decreases left ventricular size in a porcine model of congestive heart failure. Formulations containing fosinopril have been used in the treatment of hypertension and congestive heart failure.

Fosinoprilat, an active phosphinic acid metabolite of prodrug fosenopril, is activated by esterases in vivo. Fosinoprilat binds zinc with phosphinic acid group.

JBIR-22 is a natural inhibitor for protein−protein interaction of the homodimer of proteasome assembly factor 3.